Login
$DNTH
$89.20 -$0.35 (0.39%) After hours

$DNTH SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G/A
12 Nov 2026 Form 4: Savitz Ryan, EVP, CFO & CBO

Received 100,713 shares by exercise or conversion ($1.95M) · Sold 100,713 shares ($9.12M) · Received 2,561 shares by exercise or conversion ($56.1K) · 5 more

09 Nov 2026 144
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneurop...

30 Oct 2026 SCHEDULE 13G
18 Sep 2026 Form 4: Carr Edward, CHIEF ACCOUNTING OFFICER

Received 20,000 shares by exercise or conversion ($358K) · Sold 20,000 shares ($2.03M)

18 Sep 2026 S-3ASR
17 Sep 2026 144
03 Sep 2026 Form 4: Randhawa Simrat, EVP, Head of R&D

Received 23,124 shares by exercise or conversion ($477K) · Sold 23,124 shares ($2.46M)

01 Sep 2026 144
19 Aug 2026 Form 4: Read Simon, Director

Received 2,778 shares by exercise or conversion ($51K) · Sold 2,778 shares ($327K)

14 Aug 2026 Form 4: Veness Adam M, SVP, General Counsel and Sec.

Received 15,000 shares by exercise or conversion ($273K)

14 Aug 2026 SCHEDULE 13G/A
13 Aug 2026 SCHEDULE 13G
11 Aug 2026 Form 4: McGeorge Anne, Director

Received 7,750 shares by exercise or conversion ($97K) · Sold 7,750 shares ($845K)

11 Aug 2026 Form 4: Read Simon, Director

Received 2,777 shares by exercise or conversion ($51K) · Sold 2,777 shares ($304K)

11 Aug 2026 Form 4: Veness Adam M, SVP, General Counsel and Sec.

Received 3,833 shares by exercise or conversion ($68.5K) · Sold 3,833 shares ($424K) · Received 16,167 shares by exercise or conversion ($289K) · 1 more

10 Aug 2026 144
10 Aug 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support